Skip to main content
Premium Trial:

Request an Annual Quote

FDA Authorizes Quest Diagnostics SARS-CoV-2/Flu Test With Self-Collection Kit for Emergency Use

NEW YORK  – The US Food and Drug Administration on Friday evening granted Emergency Use Authorization for the first time to a diagnostic test for at-home, self-collection of patient samples for the detection of SARS-CoV-2 and influenza A/B.

The FDA authorized Quest Diagnostic's RC COVID-19  +Flu RT-PCR test for prescription use with the company's Self-Collection Kit for COVID-19 +Flu by individuals suspected of having a respiratory infection consistent with the coronavirus. If a healthcare provider determines that self-collection is appropriate for use with the test and self-collection kit, a patient can collect the sample at home and ship it to a Quest laboratory for analysis.

The test is for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, and/or influenza B virus in nasal swab specimens, the FDA said. Testing is limited to labs designated by Quest that are CLIA certified and can perform high-complexity tests.

"With the authorization of this test, the FDA is helping to address the ongoing fight against COVID-19 while in the middle of the flu season, which is important for many, including the most vulnerable of Americans," FDA Commissioner Stephen Hahn said in a statement.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.